Organogenesis Holdings Inc. (NASDAQ:ORGO) Shares Sold by Allspring Global Investments Holdings LLC

Allspring Global Investments Holdings LLC reduced its holdings in Organogenesis Holdings Inc. (NASDAQ:ORGO) by 5.8% in the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 270,916 shares of the company’s stock after selling 16,688 shares during the quarter. Allspring Global Investments Holdings LLC owned approximately 0.21% of Organogenesis worth $899,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Bank of Montreal Can increased its stake in Organogenesis by 8.7% during the first quarter. Bank of Montreal Can now owns 21,517 shares of the company’s stock worth $165,000 after acquiring an additional 1,721 shares during the last quarter. Ameritas Investment Partners Inc. increased its stake in Organogenesis by 80.1% during the first quarter. Ameritas Investment Partners Inc. now owns 5,386 shares of the company’s stock worth $41,000 after acquiring an additional 2,396 shares during the last quarter. Yousif Capital Management LLC increased its stake in Organogenesis by 3.5% during the first quarter. Yousif Capital Management LLC now owns 74,492 shares of the company’s stock worth $568,000 after acquiring an additional 2,495 shares during the last quarter. Credit Suisse AG increased its stake in Organogenesis by 3.7% during the second quarter. Credit Suisse AG now owns 92,961 shares of the company’s stock worth $454,000 after acquiring an additional 3,330 shares during the last quarter. Finally, Legal & General Group Plc increased its stake in Organogenesis by 2.4% during the fourth quarter. Legal & General Group Plc now owns 167,959 shares of the company’s stock worth $452,000 after acquiring an additional 3,903 shares during the last quarter. 39.48% of the stock is currently owned by institutional investors and hedge funds.

Organogenesis Trading Down 8.9 %

Shares of ORGO opened at $2.05 on Thursday. The company has a market capitalization of $269.19 million, a P/E ratio of 25.63 and a beta of 1.48. Organogenesis Holdings Inc. has a one year low of $1.79 and a one year high of $4.50. The company has a debt-to-equity ratio of 0.24, a quick ratio of 2.60 and a current ratio of 2.95. The stock has a 50-day moving average price of $2.55 and a 200 day moving average price of $3.06.

Organogenesis (NASDAQ:ORGO) last issued its quarterly earnings results on Wednesday, August 9th. The company reported $0.04 EPS for the quarter, beating analysts’ consensus estimates of $0.02 by $0.02. Organogenesis had a return on equity of 5.65% and a net margin of 2.20%. The firm had revenue of $117.32 million during the quarter, compared to the consensus estimate of $115.25 million. Sell-side analysts forecast that Organogenesis Holdings Inc. will post -0.01 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently issued reports on the company. BTIG Research lowered their target price on Organogenesis from $10.00 to $4.00 and set a “buy” rating for the company in a research note on Thursday, August 10th. Morgan Stanley lowered their target price on Organogenesis from $5.00 to $3.00 and set an “equal weight” rating for the company in a research note on Friday, August 11th.

About Organogenesis

Organogenesis Holdings Inc, a regenerative medicine company, develops, manufactures, and commercializes solutions for the advanced wound care, and surgical and sports medicine markets in the United States. The company's advanced wound care products include Affinity, an amniotic membrane wound covering in which viable cells growth factors/cytokines, and ECM proteins in the native tissue are preserved; Novachor, a chorion membrane wound covering in which viable cells, growth factors/cytokines, and ECM proteins are preserved; Apligraf, a bioengineered living cell therapy that produce spectrum of cytokines and growth factors; Dermagraft, a bioengineered product that produces human collagen, ECM, proteins, and cytokines; NuShield, a wound covering amnion and chorion membranes for spongy/intermediate layer intact; and PuraPly, a antimicrobial barrier that enables conformability and fluid drainage.